JP2017526747A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526747A5
JP2017526747A5 JP2017530956A JP2017530956A JP2017526747A5 JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5 JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5
Authority
JP
Japan
Prior art keywords
manufacturing process
process according
crystallized particles
mixture
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526747A (ja
JP6591546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/046525 external-priority patent/WO2016032950A1/en
Publication of JP2017526747A publication Critical patent/JP2017526747A/ja
Publication of JP2017526747A5 publication Critical patent/JP2017526747A5/ja
Application granted granted Critical
Publication of JP6591546B2 publication Critical patent/JP6591546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530956A 2014-08-25 2015-08-24 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス Active JP6591546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
US62/041,341 2014-08-25
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019169473A Division JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Publications (3)

Publication Number Publication Date
JP2017526747A JP2017526747A (ja) 2017-09-14
JP2017526747A5 true JP2017526747A5 (enExample) 2019-09-12
JP6591546B2 JP6591546B2 (ja) 2019-10-16

Family

ID=55347322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530956A Active JP6591546B2 (ja) 2014-08-25 2015-08-24 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス
JP2019169473A Pending JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019169473A Pending JP2019210296A (ja) 2014-08-25 2019-09-18 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス

Country Status (20)

Country Link
US (5) US10064859B2 (enExample)
EP (2) EP3865476B1 (enExample)
JP (2) JP6591546B2 (enExample)
CN (2) CN111454207B (enExample)
AU (2) AU2015306910B2 (enExample)
CA (1) CA2959329C (enExample)
CY (1) CY1124058T1 (enExample)
DK (1) DK3185867T3 (enExample)
ES (2) ES2994850T3 (enExample)
HR (1) HRP20210551T1 (enExample)
HU (1) HUE054641T2 (enExample)
IL (1) IL250661B (enExample)
LT (1) LT3185867T (enExample)
MA (2) MA40480B1 (enExample)
PL (1) PL3185867T3 (enExample)
PT (1) PT3185867T (enExample)
RS (1) RS61709B1 (enExample)
SI (1) SI3185867T1 (enExample)
SM (1) SMT202100212T1 (enExample)
WO (1) WO2016032950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
PL3185867T3 (pl) * 2014-08-25 2021-11-22 Alkermes Pharma Ireland Limited Sposób krystalizacji pochodnych arypiprazolu w formulacjach o przedłużonym uwalnianiu do leczenia schizofrenii
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
WO2019020821A1 (en) 2017-07-28 2019-01-31 Interquim, S.A. PROCESS FOR THE PREPARATION OF LAUROXIL ARIPIPRAZOLE
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
US9248048B2 (en) * 2007-08-03 2016-02-02 Neodyne Biosciences, Inc. Wound or skin treatment devices and methods
CN101932327A (zh) 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
US9034867B2 (en) * 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2013142198A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
EP3718536A1 (en) * 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
PL3185867T3 (pl) * 2014-08-25 2021-11-22 Alkermes Pharma Ireland Limited Sposób krystalizacji pochodnych arypiprazolu w formulacjach o przedłużonym uwalnianiu do leczenia schizofrenii

Similar Documents

Publication Publication Date Title
JP2018528985A5 (enExample)
CN104150507B (zh) 空壳型小晶粒zsm-5分子筛的一步制备法
JP2018193405A5 (enExample)
TWI520911B (zh) 奈米銀線的製備方法
HRP20210551T1 (hr) Postupak kristalizacije derivata aripiprazola u formulacijama sa produženim oslobađanjem za liječenje shizofrenije
JP2015536307A5 (enExample)
JP2017505347A5 (enExample)
JP2016000763A5 (enExample)
JP2019505532A5 (enExample)
JP5654462B2 (ja) 貧溶媒添加法による２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
CN105107462A (zh) 一种氧化石墨烯-金属有机骨架纳米复合材料的制备方法
JP2016041643A5 (ja) 中空シリカ粒子の製造方法及び中空シリカ粒子
CN104744712A (zh) 一种二元胶体晶体的快速制备方法
JP2017160107A5 (enExample)
JP2016074548A5 (enExample)
CN106083963A (zh) 一种索非布韦晶型6的制备方法
JP2013530948A5 (enExample)
JP2021529175A5 (enExample)
JP2018502165A5 (enExample)
CN106604916A (zh) 钾离子竞争性酸阻滞剂的晶型及其制备方法
CN104447459A (zh) 异维a酸的新晶型及其制备方法与应用
FI3204158T3 (fi) Heterogeenisen vaihtoesterointikatalyytin valmistusmenetelmä
JP2020500907A5 (enExample)
CN106082248A (zh) 一种不同形貌二氧化硅微球的制备方法
CN104193747B (zh) 替卡格雷无定形的制备